- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.06. | Investors sweet on Nektar as phase 2b eczema success doubles share price | ||
| 24.06. | Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators | ||
| 23.06. | BrightGene tops Novo drug in diabetes ahead of Zepbound showdown | ||
| 23.06. | Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication | ||
| 23.06. | Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash | ||
| 23.06. | Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace | ||
| 23.06. | Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed | ||
| 23.06. | Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring | ||
| 23.06. | Otsuka pens $670M pact to point Harbour's preclinical T-cell engager to autoimmune disease | ||
| 23.06. | Novo's injectable amycretin yet to hit weight-loss plateau, suggesting Zepbound-beating potential | ||
| 23.06. | Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test | ||
| 20.06. | FDA blocks new clinical trials that ship cells from US to China | ||
| 20.06. | Syncona blames 'challenging' market for shift in biotech investment strategy | ||
| 20.06. | Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail | ||
| 20.06. | Industry 'deeply disappointed' as FDA puts cell and gene therapy chief on administrative leave | ||
| 18.06. | Zealand Pharma's GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks | ||
| 18.06. | US accused of denying R&D grants for biotechs based on international investor links | ||
| 18.06. | Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY | ||
| 18.06. | Scholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trial | ||
| 18.06. | China's rapid rise creates 'heightened risks' for pharma: PwC | ||
| 17.06. | FDA launches new priority review voucher program for biopharmas that 'align with national priorities' | ||
| 17.06. | Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans | ||
| 17.06. | Aptose CEO props up biotech's finances to prevent company from going bust | ||
| 17.06. | Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2 | ||
| 17.06. | Ventyx posts phase 2 Parkinson's data ahead of potential talks with Sanofi |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .